[go: up one dir, main page]

NO20071314L - Peptidiske vasopressinreseptoragonister - Google Patents

Peptidiske vasopressinreseptoragonister

Info

Publication number
NO20071314L
NO20071314L NO20071314A NO20071314A NO20071314L NO 20071314 L NO20071314 L NO 20071314L NO 20071314 A NO20071314 A NO 20071314A NO 20071314 A NO20071314 A NO 20071314A NO 20071314 L NO20071314 L NO 20071314L
Authority
NO
Norway
Prior art keywords
receptor agonists
compounds
vasopressin receptor
peptidic vasopressin
peptidic
Prior art date
Application number
NO20071314A
Other languages
English (en)
Other versions
NO342449B1 (no
Inventor
Kazimierz Wisniewski
Claudio Schteingart
Regent Laporte
Robert Felix Galyean
Pierre J-M Riviere
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of NO20071314L publication Critical patent/NO20071314L/no
Publication of NO342449B1 publication Critical patent/NO342449B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

S a m m e n d r a g Foreliggende oppfinnelse vedrører nye forbindelser, farmasøytiske sammensetninger omfattende det samme, anvendelse av forbindelsene for fremstilling av et medikament for behandling av inter alia sjokktilstander samt en fremgangsmåte for behandling av tilstandene, hvori forbindelsene administreres. Forbindelsene er representert ved den generelle formel (I), som ytterligere definert i beskrivelsen.
NO20071314A 2004-08-11 2007-03-12 Peptidiske vasopressinreseptoragonister. NO342449B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60037704P 2004-08-11 2004-08-11
EP04019029 2004-08-11
PCT/US2005/027772 WO2006020491A1 (en) 2004-08-11 2005-08-03 Peptidic vasopressin receptor agonists

Publications (2)

Publication Number Publication Date
NO20071314L true NO20071314L (no) 2007-05-10
NO342449B1 NO342449B1 (no) 2018-05-22

Family

ID=34926126

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071314A NO342449B1 (no) 2004-08-11 2007-03-12 Peptidiske vasopressinreseptoragonister.

Country Status (25)

Country Link
US (2) US8148319B2 (no)
EP (1) EP1776133B1 (no)
JP (1) JP4664363B2 (no)
KR (1) KR100884323B1 (no)
CN (1) CN1964732B (no)
AR (1) AR050914A1 (no)
AT (1) ATE509944T1 (no)
AU (1) AU2005274070B2 (no)
BR (1) BRPI0511466B8 (no)
CA (1) CA2567797C (no)
DK (1) DK1776133T3 (no)
ES (1) ES2366702T3 (no)
IL (1) IL178690A (no)
JO (1) JO2937B1 (no)
MX (1) MX2007001396A (no)
NO (1) NO342449B1 (no)
NZ (1) NZ550707A (no)
PL (1) PL1776133T3 (no)
PT (1) PT1776133E (no)
RU (1) RU2355701C2 (no)
SA (1) SA05260254B1 (no)
SI (1) SI1776133T1 (no)
TW (1) TWI364291B (no)
WO (1) WO2006020491A1 (no)
ZA (1) ZA200700772B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2937B1 (en) * 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
RU2415149C2 (ru) * 2006-02-10 2011-03-27 Ферринг Б.В. Пептидные соединения
ES2566143T3 (es) * 2006-02-13 2016-04-11 Ferring B.V. Uso de agonistas peptídicos de receptor de vasopresina
WO2009037586A2 (en) * 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
ES2629131T3 (es) 2008-09-17 2017-08-07 Chiasma Inc. Composiciones farmacéuticas y métodos de suministro relacionados.
JO3109B1 (ar) * 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
US9388214B2 (en) * 2014-11-05 2016-07-12 Ferring B.V. V1A receptor agonists
RU2634272C1 (ru) * 2016-08-10 2017-10-24 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения
IL265761B2 (en) 2016-10-21 2024-11-01 Amryt Endo Inc Oral terlipressin compositions for use in treatment of ascites
US11033601B2 (en) 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
CN109748950B (zh) * 2017-11-02 2020-10-30 深圳翰宇药业股份有限公司 一种固相合成血管升压素受体肽激动剂selepressin的方法
EP3517543B1 (en) * 2018-01-30 2020-11-04 Bachem AG Manufacture of glucagon peptides
EP3880226A1 (en) 2018-11-15 2021-09-22 Ferring B.V. Compounds, compositions and methods for treating sepsis
KR20230041029A (ko) * 2020-07-17 2023-03-23 파마인 코포레이션 V1a 수용체 부분 효능제 및 이용 방법
CN120265306A (zh) * 2022-09-30 2025-07-04 辉凌公司 调节平均动脉压的混合型血管加压素受体激动剂-拮抗剂

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE651400A (no) 1963-04-05 1965-02-04
NL129421C (no) 1963-08-30 1900-01-01
CS235151B1 (cs) 1982-08-26 1985-05-15 Michal Lebl Způsob dělení Dal isomerů analogů oxytocinu
US4829051A (en) 1983-04-05 1989-05-09 Vega Laboratories, Inc. N-substituted derivatives of 1-desaminovasopressin
US4483794A (en) 1983-05-10 1984-11-20 Ceskoslovenska Akademie Ved Analogs of neurohypophysial hormones
CS242062B1 (cs) 1984-08-23 1986-04-17 Milan Zaoral Vasopresinová a vasotocinová analoga a způsob jejich přípravy
SE457055B (sv) 1986-08-18 1988-11-28 Ferring Ab Topisk straalskyddsgel foer mukosa innehaallande kaerlsammandragande substanser
SE469473B (sv) 1987-10-07 1993-07-12 Ferring Ab Vasoaktiva peptider
SE502644C2 (sv) * 1990-02-27 1995-11-27 Ferring Ab Vasoaktiva vasotocinderivat
RU2063979C1 (ru) 1992-02-24 1996-07-20 Всесоюзный научно-исследовательский институт технологии кровезаменителей и гормональных препаратов Пептиды последовательности окситоцина
US5516795A (en) * 1994-09-12 1996-05-14 Abbott Laboratories Heteroatom substituted propanyl derivatives having 5-lipoxygenase inhibitory activity
RU2073010C1 (ru) * 1994-10-26 1997-02-10 Российско-германское совместное предприятие "Константа" Способ синтеза лизин-вазопрессина в растворе
GB9617021D0 (en) 1996-08-13 1996-09-25 Salpep Biotechnology Inc Novel peptides for treatment of inflammation and shock
SE9701162D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
SE9701161D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
WO1999013092A1 (en) 1997-09-11 1999-03-18 The Public Health Research Institute Of The City Of New York, Inc. Enhancement of mucosal antibody responses by interleukin-6
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE0001440D0 (sv) 2000-04-18 2000-04-18 Entretech Medical Ab A drug against climacteric disorders
WO2002064740A2 (en) 2001-02-09 2002-08-22 Cognetix, Inc. Cone snail peptides
AU2003220919A1 (en) 2002-03-29 2003-10-13 Wakamoto Pharmaceutical Co., Ltd. Drugs for increasing lacrimal fluid
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
CA2500831A1 (en) 2002-10-03 2004-04-15 Eric Hollander Treatment of autism and similar disorders
CA2557520C (en) 2003-02-26 2011-09-13 Donald W. Landry A method for stabilizing blood pressure in hemodialysis subjects
JO2937B1 (en) * 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
RU2415149C2 (ru) * 2006-02-10 2011-03-27 Ферринг Б.В. Пептидные соединения
ES2566143T3 (es) * 2006-02-13 2016-04-11 Ferring B.V. Uso de agonistas peptídicos de receptor de vasopresina
US8148349B2 (en) 2006-12-20 2012-04-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
RU2342949C1 (ru) 2007-03-26 2009-01-10 Юрий Георгиевич Жуковский Применение [дезамино-1, изолейцин-3, аргинин-8]вазопрессина в качестве средства для увеличения выведения почкой солей натрия и усиления обратного избирательного всасывания из почечных канальцев в кровь воды-растворителя

Also Published As

Publication number Publication date
JP2008509221A (ja) 2008-03-27
JP4664363B2 (ja) 2011-04-06
CA2567797C (en) 2012-07-10
DK1776133T3 (da) 2011-07-18
CN1964732A (zh) 2007-05-16
IL178690A0 (en) 2007-02-11
KR100884323B1 (ko) 2009-02-18
CN1964732B (zh) 2011-03-02
BRPI0511466B8 (pt) 2021-05-25
ES2366702T3 (es) 2011-10-24
PT1776133E (pt) 2011-09-02
SA05260254B1 (ar) 2008-05-19
US20120196808A1 (en) 2012-08-02
AR050914A1 (es) 2006-12-06
AU2005274070B2 (en) 2008-02-07
KR20070029183A (ko) 2007-03-13
RU2355701C2 (ru) 2009-05-20
RU2007101238A (ru) 2008-09-20
CA2567797A1 (en) 2006-02-23
US8148319B2 (en) 2012-04-03
SI1776133T1 (sl) 2011-07-29
ATE509944T1 (de) 2011-06-15
HK1100280A1 (en) 2007-09-14
PL1776133T3 (pl) 2011-09-30
TWI364291B (en) 2012-05-21
EP1776133A4 (en) 2008-12-31
ZA200700772B (en) 2008-09-25
JO2937B1 (en) 2016-03-15
EP1776133B1 (en) 2011-05-18
BRPI0511466B1 (pt) 2018-01-23
AU2005274070A1 (en) 2006-02-23
US8778881B2 (en) 2014-07-15
IL178690A (en) 2013-10-31
EP1776133A1 (en) 2007-04-25
US20090054309A1 (en) 2009-02-26
NO342449B1 (no) 2018-05-22
WO2006020491A1 (en) 2006-02-23
NZ550707A (en) 2010-07-30
BRPI0511466A (pt) 2007-12-26
MX2007001396A (es) 2007-04-19
TW200612976A (en) 2006-05-01

Similar Documents

Publication Publication Date Title
NO20071314L (no) Peptidiske vasopressinreseptoragonister
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
TW200615266A (en) Organic compounds
TW200505903A (en) CGRP receptor antagonists
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
ATE433447T1 (de) Pyrimiidinverbindungen
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
WO2009155121A3 (en) Inhibitors of pi3 kinase
NO20055219L (no) Nye forbindelser
ATE411323T1 (de) Cgrp-rezeptorantagonisten
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
ATE466860T1 (de) Cgrp-rezeptorantagonisten
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
ATE503755T1 (de) Cgrp-rezeptorantagonisten
WO2006041830A3 (en) Cgrp receptor antagonists
NO20083853L (no) Nye forbindelser
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees